Lutropin (LH) bears asparagine-linked oligosaccharides terminating with the unique sequence SO4-4GalNAc31-4GlcNAcfI-2Mana, whereas follitropin (FSH) bears oligosaccharides terminating predominantly with the sequence Siaa-Gall-4GlcNAcI31-2Mana, where Sia is sialic acid. We previously identified a glycoprotein-hormone-specific N-acetylgalacamine-tsferase (GaINAc-transferase) that recognizes a peptide-recognition marker(s) present on the common glycoprotein hormone a subunit and 13 subunits of human chorionic gonadotropin and LH but not on the (3 subunit of FSH. We have now identified an amino acid sequence motif, Pro-Leu-Arg, that is essential for recognition by the GaINAc-transferase. This tripeptide sequence is found 6-9 residues on the amino-terminal side of a glycosylated asparagine on the a subunit and (3 subunits of LH and human chorionic gonodatro,pin but is not present on the P subunit of FSH. The presence of this motif accounts for the differences in LH and FSH oligosaccharide structures. Additional proteins containing this recognition motif have been identified and were determined to bear sulfated oligosaccharides with the same structures as those on the glycoprotein hormones, indicating that these structures are not restricted to the glycoprotein hormones.
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Kupffer cells and that recognizes oligosaccharides terminating with the sequence S04-4GalNAcf91-4GlcNAc/B1-2Mana (17) .
In earlier studies, we demonstrated (8) the presence of a glycoprotein-hormone-specific N-acetylgalactosaminetransferase (GalNAc-transferase) in membranes from the anterior pituitary that will transfer GalNAc to the terminal GlcNAc moieties of GlcNAc2Man3GlcNAc2Asn (8) . When this oligosaccharide is located on the a subunit or the /3 subunits of human (h) CG (hCGf3) or LH (hLH/B), the apparent Km for GalNAc transfer is reduced from 1-2 mM to <15 tiM, due to the presence ofa peptide-recognition marker (9) . We have now identified essential elements of this peptide-recognition marker and determined that it is not present on the m subunit of FSH (FSH/8), accounting for the lack of recognition of this hormone by the GalNAc-transferase. Further, we have identified a similar motif on other glycoproteins and found that they bear the same sulfated oligosaccharide structure. It is, therefore, likely that this unique type of oligosaccharide structure plays an important role in the biologic behavior of a number of glycoproteins that are released into the circulation.
Among the many asparagine-linked oligosaccharides that have been characterized, there are only a small number of clearly unique structures that are found on highly restricted populations of glycoproteins. As a result, the presence of such structures suggests an important biologic function. One example is the sulfated asparagine-linked oligosaccharides found on specific members of the glycoprotein hormone family (1) . The glycoprotein hormones lutropin (LH), follitropin (FSH), thyrotropin, and chorionic gonadotropin (CG) are dimeric proteins with highly homologous hormonespecific l3 subunits and identical a subunits (2, 3) . Despite having closely related peptide structures at the primary, secondary, and tertiary levels, their asparagine-linked oligosaccharides are distinct. For example, LH and FSH are synthesized by the same cell, the gonadotroph (4, 5), yet the asparagine-linked oligosaccharides on LH terminate with the sequence SO4-4GalNAc/31-4GlcNAc,81-2Mana whereas those on FSH predominantly terminate with Siaa-Galp1-4GlcNAcB1-2Mana, where Sia is sialic acid (1, 6, 7) . Few other glycoproteins synthesized in the pituitary terminate with the sequence SO4-4GalNAc/31-4GlcNAc,81-2Mana, indicating this form of posttranslational modification is highly specific. We recently determined that the presence of sulfated as opposed to sialylated oligosaccharides on LH has a major impact on its circulatory half-life (16) . This reflects the rapid removal of native bovine (b) LH from the serum by a receptor that is present on hepatic endothelial cells and MATERIALS AND METHODS GaINAc-Transferase Assays. Assays were performed with GaINAc-transferase (0.79 unit/mg), which had been enriched 165-fold from bovine pituitaries and was stored at 0.2 mg/ml in 50 mM Hepes, pH 7.5/10 mM KCI/20% (vol/vol) glycerol/ 0.1% Triton X-100 at -800C. The transferase reactions were incubated at 370C and contained 4 x 10-3 unit of GalNActransferase, 25 mM Hepes, 5 mM KCI, 20%6 glycerol, 0.1% Triton X-100, 6 30 ,ul of 30% (vol/vol) acetic acid was added followed by 0.5 ml ofdistilled H20. The cyclohexanedione-modified glycopeptides were eluted as single peaks, which differed in retention time from the unmodified glycopeptides, when isolated by reverse-phase HPLC. After modification, arginine was no longer detected upon amino acid analysis. The "unmodified" glycopeptides used for comparison were treated identically except that 1,2-cyclohexanedione was omitted.
Peptide Synthesis. Peptides were synthesized on a Ramps processor (DuPont) according to the manufacturer's instructions. All peptides were purified sequentially by reversephase HPLC, S-Sepharose cation-exchange chromatography, and gel filtration on Sephadex G-10. Peptides were quantitated by amino acid analysis.
RESULTS
A 22-Amino Acid Glycopeptide Is Recognized by the GalNAc-Transferase. Our previous studies established that peptide recognition is required for specific addition ofGaINAc to oligosaccharides on hCG8, LHB, and the a subunits. GalNAc and sulfate are not present on the oligosaccharides of native hCG and recombinant LH expressed in CHO cells, due to the absence of the GalNAc-and sulfotransferases in placental trophoblasts and CHO cells (8, 10) . The sialylated asparagine-linked oligosaccharides on hCG and recombinant LH can be readily converted into substrates for the GalNActransferase by removal of terminal sialic acid and galactose moieties. The lack of dependence on tertiary structure for recognition by the GaiNAc-transferase indicated that, in contrast to other forms of peptide-dependent recognition, it would be possible to locate and identify the peptide recognition marker by using proteolytic fragments of these hormones as acceptors. We therefore prepared proteolytic glycopeptide fragments from hCGa(RCM) (Fig. 1) and hCGS(RCM) (Fig. 2) for comparison as GaINAc-transferase substrates. The kinetic parameters determined for hCGa, hCGa(RCM), and hCGa-(35-56), a glycopeptide consisting ofamino acids 35-56 ofhCGa including the glycosylation site at Asn-52, are summarized in Table 1 . As we had determined (9) , the apparent Km for transfer of GalNAc to oligosaccharides on hCGa(RCM) is slightly decreased compared to native hCGa. The apparent Km of 9.8 ,uM for transfer of GalNAc to the oligosaccharide acceptor on hCGa-(35-56) does not differ significantly from that for transfer to the oligosaccharides on hCGa(RCM) ( Table 1) . Therefore, all of the information required for recognition of the a subunit by the GalNAc-transferase resides within this 22-amino acid glycopeptide fragment.
Localizato of the Peptide-Recognition Sequence on hCGa. Additional glycopeptides were prepared to further localize the amino acids mediating recognition of hCGa by the GalNAc-transferase and to determine if additional recognition sequences might be present. The glycopeptides shown in Fig. 1 oligosaccharides on hCGa(RCM) is more than 100-fold greater than for addition to the same oligosaccharide structures on either hCGa-(52-63) or transferrin (9) . In control experiments using bovine j-1,4-galactosyltransferase, an enzyme that requires only terminal GlcNAc for transfer and is not influenced by the underlying protein structure (11), equal amounts of galactose were added to the oligosaccharides on hCGa-(35-56) and hCGa-(52-63) confirming that the same amount of GlcNAc2Man3GlcNAc2Asn was present on both glycopeptides. The amino acids mediating recognition by the GalNAc-transferase must, therefore, be located between amino acids 35 and 51 of the human a subunit.
hCGa has a second glycosylation site at Asn-78 (Fig. 1) . The peptide sequence surrounding this site does not resemble that surrounding Asn-52. A glycopeptide, hCGa-(76-91), containing this glycosylation site was also tested as substrate for the GalNAc-transferase (Fig. 1) . GalNAc was transferred ,uM, respectively (9). The catalytic efficiencies for transfer of GalNAc to hCG.3(RCM) and hCGa(RCM) are nearly identical (9) , as are the rates of transfer seen in Figs. 1 and 2 . GalNAc was transferred to the Asn-linked oligosaccharide on Asn-13 of the proteolytic fragment hCG/B- (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) at half the rate of transfer to hCG,(RCM) but 50-fold greater than the rate oftransfer to transferrin. The marked decrease in the rate of GalNAc transfer when residues 3-8 were removed to produce hCGf-(9-20) (Fig. 2) was particularly striking. The GalNAc-transferase adds GalNAc to the oligosaccharide of hCGf3-(9-20) at 20% the rate of transfer to the same oligosaccharide on hCGB-(3-20), indicating that the aminoterminal 6 residues of hCGB-(3-20) are required for efficient recognition of hCG(3.
GaINAc-Transferase Substrates Contain the Sequence ProLeu-Arg. hCGB, bLH,, and hCGa contain a peptiderecognition marker for the glycoprotein-hormone-specific GalNAc-transferase that is not present on hFSH,3 (9) . Alignment of the amino acid sequences of the glycoproteinhormone subunits in the regions of their glycosylation sites (Fig. 3 ) reveals a number of features that may account for the pattern of recognition of the hormone subunits and the glycopeptides described above. hCGB and bLHP contain the sequence Pro-Leu-Arg 6 residues on the amino-terminal side of an asparagine glycosylation site. The same tripeptide is found 9 residues on the amino-terminal side of the glycosylated Asn-52 of hCGa. In contrast, the Pro-Leu-Arg tripeptide is not present on hFSHB due to an amino-terminal truncation of FSHf3 compared to LH3 and CGB. The ProLeu-Arg tripeptide is included within the amino-terminal 6 residues, Ser-Lys-Glu-Pro-Leu-Arg, of hCGf-(3-20) that are required for efficient recognition by the GalNAc-transferase. hCGa-(52-63) and hCGa-(76-21) do not contain a Pro-LeuArg sequence and are not recognized by the glycoproteinhormone-specific GalNAc-transferase. Therefore, the presence of the tripeptide Pro-Leu-Arg 6-9 residues on the amino-terminal side of an asparagine glycosylation site appears to be necessary for recognition by the glycoproteinhormone-specific GalNAc-transferase.
Chemical Modification of Arginine Destroys the Recognition Marker. To directly implicate the Pro-Leu-Arg sequence as an essential element of the GalNAc-transferase recognition marker, we chemically modified the arginine residues present in hCGa-(35-56) and hCGP-(3-20) using 1,2-cyclohexanedione. The conditions used for chemical modification of arginine were chosen to produce a stable neut4al product, thus destroying the cationic character of the arijnine residue (12) .
The rate of GalNAc transfer to hCGa-(35-56) with modified arginine residues at positions 35 and 42 was reduced to 10% Biochemistry: Smith and Baenziger that of unmodified hCGa-(35-56) (Fig. 4A) . Likewise modification of the three arginine residues in hCGf-(3-20) reduced the rate of GaINAc transfer to 10% that of unmodified hCGfi-(3-20) (Fig. 4B) . In contrast, treatment of either hCGa-(35-56) or hCGI3-(3-20) with 1,2-cyclohexanedione under conditions that result in a cationic product (13) did not significantly alter recognition by the GalNAc-transferase (data not shown). Thus, it appears to be the cationic nature of arginine that is essential for recognition by the GalNActransferase. Since the only arginine residues at homologous positions in hCGa-(35-56) and hCG/3-(3-20) are both a part of the Pro-Leu-Arg motif, the loss of recognition after modification strongly implicates these specific arginine residues as an essential part of the recognition marker used by the GalNAc-transferase.
Inhibition of the GaINAc-Transferase by Synthetic Peptides. The presence of the peptide recognition marker on glycopeptide substrates reduces the apparent Km for the oligosaccharide acceptor but is not required for transfer of GalNAc (8) , suggesting the peptide marker and the oligosaccharide are recognized independently. If this is the case, peptides containing the recognition marker but no oligosaccharide should act as competitive inhibitors of the GalNAc-transferase. Since hCGa-(35-56) contains all ofthe necessary information required for recognition by the GalNAc-transferase, we prepared the identical nonglycosylated peptide synthetically. A peptide with the same sequence as hCGa-(35-56) showed a level of inhibition significantly better than a peptide containing the same amino acids in a random order (Fig. 5) . The level of inhibition seen with the scrambled peptide was similar to that obtained with a number of other unrelated peptides of similar size but differing composition. Digestion with Pronase completely abolished inhibition by either the peptide with the same sequence as hCGa-(35-56) or the scrambled peptide (data not shown), indicating that in both cases inhibition is due to peptide and not to nonpeptide contaminants. Replacement of the Pro-Leu-Arg sequence of the peptide representing hCGa-(35-56) with Ala-Ala-Ala significantly reduced its ability to inhibit the GalNActransferase (Fig. 5) . Therefore, inhibition of GalNAc transfer by synthetic peptides is sequence-specific, requiring the Pro-Leu-Arg motif for maximal inhibition. DISCUSSION Based on the evidence presented here, we conclude that the tripeptide sequence Pro-Leu-Arg is the basis for recognition (1, 6, 7) . In previous studies we determined (9) that combination of FSHP with the a subunit results in masking of the recognition sequence on the a subunit. The degree to which the Pro-Leu-Arg recognition sequence on the a subunit is masked most likely accounts for the extent to which oligosaccharides on FSH dimers bear S044GalNAc. hCGB and hCGa contain the recognition sequence and the hCG dimer is a substrate for the GalNActransferase in vitro; however, hCG synthesized by placental trophoblasts does not bear sulfated oligosaccharides because neither the glycoprotein-hormone-specific GalNAc-transferase nor the sulfotransferase is expressed in placenta (8) .
We have searched the NBRF protein data base for additional glycoproteins containing a Pro-Xaa-Arg/Lys sequence located 6-9 residues on the amino-terminal side of an AsnXaa-Ser/Thr. Among the glycoproteins identified by these criteria, two have been reported to contain sulfated asparagine-linked oligosaccharides. Rat proopiomelanocortin and the glycosylated form of its cleavage product corticotropin contain sulfated asparagine-linked oligosaccharides (14) . A tripeptide sequence, Pro-Val-Lys, is located 7 residues on the amino-terminal side of the asparagine glycosylation site found within corticotropin. Lipoprotein-associated coagulation inhibitor, synthesized by human umbilical vein endothelial cells, can be metabolically labeled on its asparaginelinked oligosaccharides with [355]Q4 (G. J. Broze, personal communication). Lipoprotein-associated coagulation inhibitor has the tripeptide sequence Pro-Phe-Lys located 9 residues on the amino-terminal side of one of its glycosylation sites (15) . We have characterized the asparagine-linked oligosaccharides on corticotropin synthesized in AtT-20 cells (T. P. Skelton, S. Kumar, P.L.S., and J.U.B., unpublished data) and on lipoprotein-associated coagulation inhibitor synthesized in 293 cells (P.L.S., T. P. Skelton, M. C. Beranek, G. J. Broze, and J.U.B., unpublished data) and found that >70% of their asparagine-linked oligosaccharides terminate with the sequence S04-4GalNAcf31-4GlcNAcp1-2Mana. Thus, the sulfated oligosaccharide structures that we originally identified on the pituitary glycoprotein hormones are also present on other glycoproteins that contain the recognition motif Pro-Xaa-Arg/Lys in close proximity to an asparagine-linked oligosaccharide.
Synthesis of the unique sulfated oligosaccharides found on the glycoprotein hormones is highly specific and tightly regulated. The presence of such unique sulfated oligosaccharides suggested that they play an important role in the biologic behavior of glycoprotein such as LH. The sulfated oligosaccharides found on LH do not affect its bioactivity at the receptor level but do have a marked impact on circulatory half-life of LH and, as a result, on its in vivo potency (16) . We have identified a receptor in hepatic reticuloendothelial cells that is specific for oligosaccharides with the terminal sequence SO4-4GalNAc/31-4GlcNAc.31-2Mana and can account for the rapid clearance of LH and other glycoproteins bearing these structures (17) . The presence of the Pro-LeuArg motif and sulfated oligosaccharide structures on other glycoproteins of diverse function and origin suggests that these structures may be of biologic significance for a number of glycoproteins found in the circulation.
